» Articles » PMID: 21487811

MKK4 Acts As a Potential Tumor Suppressor in Ovarian Cancer

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2011 Apr 14
PMID 21487811
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Our previous studies indicate that loss of MKK4 expression is associated with the progression of ovarian cancer. However, direct evidence that MKK4 inhibits the malignant phenotype of ovarian cancer cells is limited. In the current study, we investigated the mechanism relating loss of MKK4 expression to the development of ovarian cancer. Using cell growth and anchorage-independent assays, we determined that both the growth and colony-forming ability of MKK4-transfected TOV-21G cells, a line with a homozygous deletion of MKK4, were significantly reduced compared to control vector-transfected cells. Overexpression of the MKK4 gene in TOV-21G cells resulted in reduced proliferative activity and increased apoptosis. To confirm that MKK4 expression related to tumor suppress function, we used two independent but complementary approaches. MKK4 gene knockdown in OVK18#2 and MDAH2774 cells, which overexpressed MKK4, increased proliferation activity. Additionally, the engineered expression of MKK4 in SKOV3 cells, a line with low endogenous MKK4 expression, produced a phenotype similar to that of TOV-21G. Similar results were produced in tumor xenografts in nude mice. These results indicated that MKK4 acts as a tumor suppressor and may represent an important therapeutic target for the treatment of ovarian cancer.

Citing Articles

MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis.

Liu S, Huang J, Zhang Y, Liu Y, Zuo S, Li R Aging (Albany NY). 2019; 11(22):10697-10710.

PMID: 31761784 PMC: 6914392. DOI: 10.18632/aging.102485.


[Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].

Liu S, Liu Y, Li R Nan Fang Yi Ke Da Xue Xue Bao. 2017; 37(4):488-493.

PMID: 28446401 PMC: 6744108.


Downregulation of phosphorylated MKK4 is associated with a poor prognosis in colorectal cancer patients.

Wang P, Huang J, Duan Y, Zhou J, Huang P, Fan X Oncotarget. 2017; 8(21):34352-34361.

PMID: 28423721 PMC: 5470973. DOI: 10.18632/oncotarget.16128.


Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma.

Zhao L, Liu X, Yan H, Li W, Zeng X, Yang Y Nat Commun. 2016; 7:12992.

PMID: 27703150 PMC: 5059470. DOI: 10.1038/ncomms12992.


Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers.

Sharma V, Young L, Allison A, Owen K Elife. 2016; 5.

PMID: 26894955 PMC: 4769161. DOI: 10.7554/eLife.11566.


References
1.
Xin W, Yun K, Ricci F, Zahurak M, Qiu W, Su G . MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res. 2004; 10(24):8516-20. DOI: 10.1158/1078-0432.CCR-04-0885. View

2.
Su G, Hilgers W, Shekher M, Tang D, Yeo C, Hruban R . Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 1998; 58(11):2339-42. View

3.
Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman R, Velculescu V . Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther. 2006; 5(6):630-4. DOI: 10.4161/cbt.5.6.2675. View

4.
Hannon G, Rossi J . Unlocking the potential of the human genome with RNA interference. Nature. 2004; 431(7006):371-8. DOI: 10.1038/nature02870. View

5.
Yamada S, Hickson J, Hrobowski Y, Vander Griend D, Benson D, Montag A . Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002; 62(22):6717-23. View